GSK plots $30bn investment into US in latest blow to UK’s pharma sector September 17, 2025 GSK has unveiled a new plan to spend $30bn (£22bn) on research and manufacturing facilities in the US. The London-based business said the capital would be deployed over the next five years and would create hundreds of high-skilled American jobs in areas such as AI and advanced digital technologies. The investment of £4.4bn per year [...]
Merck warns UK is ‘not internationally competitive’ as it scraps £1bn London research centre September 10, 2025 Merck has pulled out of a planned £1bn London drug research centre in the latest blow to the government’s growth agenda. The US pharma giant is to lay off 127 staff alongside abandoning the construction project, which had been set to open in King’s Cross in 2027. The firm warned the UK would lag behind [...]
Global markets take a tumble as Trump pushes on with his trade war August 1, 2025 Global stocks weakened on Friday morning after US President Donald Trump hit multiple countries with a blitz of tariffs. Trump’s ambition to restructure the global trading order in his administration’s favour has sent jitters through markets on his set negotiation deadline day. The FTSE 100 is down 0.7 per cent, with UK drug maker Astrazeneca [...]
Astrazeneca plots huge $50bn US investment after ditching UK expansion plans July 22, 2025 Astrazeneca has unveiled plans to invest as much as $50bn in manufacturing and R&D in the US after ditching its UK expansion plans in a blow to the government’s industrial strategy. The Cambridge-based pharma giant said it will spend the huge sum over the next five years, including on a new manufacturing facility in Virginia, [...]
ABPI: UK aims high on life sciences, but investment lags behind July 16, 2025 The government’s newly unveiled Life Sciences Sector Plan lays out an ambition to position the UK as a global life sciences leader by 2030. But the pharmaceutical industry has pushed back, warning that without major reforms to medicine funding and pricing, the strategy risks underdelivering. Published on Wednesday as part of government’s Industrial Strategy, the [...]
Astrazeneca chief ‘wants to shift London listing to US’ July 1, 2025 The boss of Britain’s most valuable company, Astrazeneca, has reportedly voiced his preference to move the firm’s stock market listing to the United States. Sir Pascal Soriot, who has been at the helm of the pharma juggernaut since 2012, is said to have spoken privately about his desire to abandon the UK listing in favour [...]
GSK and Astrazeneca shares slump as Trump vows drug price cut May 12, 2025 GSK and Astrazeneca shares fall as Trump announces drug price cuts in a new executive order.
GSK shares rise as FTSE 100 giant ‘well positioned’ for pharma tariffs April 30, 2025 British drugmaker GSK insisted it was “well positioned” to respond to the impact of sector-specific tariffs amid widespread speculation President Donald Trump is set to target pharmaceutical imports with his tariff agenda. Trump voiced his desire to slap tariffs on pharma products in the “not too distant future”. He previously said: “We don’t make our [...]
As FTSE 100 pharma firms wait for a tariffs decision, what would drugs levies mean for consumers? April 22, 2025 For FTSE 100 businesses navigating the shifting sands of Trump’s trade war, the uncertainty surrounding the tariffs has been almost as painful as the stock market shocks. The pharmaceutical industry has been left in a particularly agonising limbo: free, for now, from the 10 per cent baseline import tax, but the US President keeps making [...]
It takes a village: Do we need to rethink our attitude to old age? April 10, 2025 We’re living for longer than ever but the boom in the elderly population is a social and political time-bomb. Could ‘later life’ communities like Auriens be the answer to the old age crisis, asks Steve Dinneen I enter a grand lobby, all lofty ceilings, marquetry floors and art deco fittings. An effusive concierge in a natty [...]